Research Groups

Related Links

Dr Andrew Wardley - Medical Oncology Breast Clinical Trials Group

Andrew Wardley is Clinical Director of The Christie NIHR/CRUK Clinical Research Facility, a member of the NCRI Breast Group and is PI and member of steering committees of a large number of phase I-III trials in early and late breast cancer.

Clinical Director of The Christie NIHR/CRUK Clinical Research Facility

Consultant & Honorary Senior Lecturer in Medical Oncology

Lead for The Christie Manchester Breast Centre Research Team

The Christie NIHR/CRUK Clinical Research Facility
The Christie NHS Foundation Trust
550 Wilmslow Road
M20 4BX

Tel: +44 (0)161 918 8281
Fax: +44 (0)161 918 7876


Vicky Lau – Team Leader
Paula Potter – Senior Research Nurse
Cathryn Jones –Senior Research Nurse
Janet Morris - Research Nurse
Jane Haslett-Evans - Research Nurse
Gemma Findlay - Research Nurse
Zoe Brammer - Research Nurse
Chloe Rands - Research Nurse

Samah Mughal – Research Portfolio Manager
Amy Kavanagh – Senior CTC
Leah Harter – Senior CTC
Sana Latif – CTC
Charlotte Burke – CTC
Anna Clarke – CTC
Karen Forshaw – CTC
Orrie Appell – CTC

I graduated from The University of Manchester in 1989, completed general medicine training in 1993, and higher specialist training in Medical Oncology, including an MSc and research doctorate in 2000. From 2001 as the Consultant Medical Oncologist for breast cancer I developed The Christie Hospital Breast Cancer Research Team to be the highest recruiters in the UK and in 2005 was one of the founding members of Manchester Breast Centre.

I am Principal/Chief Investigator on many national and international trials. I have developed new links with numerous research partners in industry and academia.

In addition to The Manchester Breast Centre I have close collaboration with other colleagues in The University of Manchester Professor Caroline Dive, Director of Clinical Experimental Pharmacology, which has led to important work detecting circulating free DNA (PI3K) in patients with breast cancer. Circulating tumour DNA is an exciting area of research and part a UK national study (plasmaMATCH-CI Nick Turner).

Since 2011 I have been Clinical Director of the Christie Hospital/NIHR Clinical Research Facility.

I am also a member of MCRC Strategy Group, MAHSC Experimental Medicine Strategy Board, and lead the systemic therapies theme for The Christie Research Strategy Committee.

Patient-derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to Metastasis

Eyre, R., Alférez, D. G., Spence, K., Kamal, M., Shaw, F. L., Simões, B. M., Santiago-Gómez, A., Sarmiento-Castro, A., Bramley, M., Absar, M., Saad, Z., Chatterjee, S., Kirwan, C., Gandhi, A., Armstrong, A. C., Wardley, A. M., O'Brien, C. S., Farnie, G., Howell, S. J. & Clarke, R. B.

Journal of Mammary Gland Biology and Neoplasia. 2016. [Epub ahead of print]

Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, Abraham J, Thomas J, Provenzano E, Hughes-Davies L, Gounaris I, McAdam K, Chan S, Ahmad R, Hickish T, Houston S, Rea D, Bartlett J, Caldas C, Cameron DA, Hayward L; ARTemis Investigators.

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.

Lancet Oncol. 2015 Jun;16(6):656-66. doi: 10.1016/S1470-2045(15)70137-3.

Hall E, Cameron D, Waters R, Barrett-Lee P, Ellis P, Russell S, Bliss JM, Hopwood P; TACT Trial Investigators.

Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001).

Eur J Cancer. 2014 Sep;50(14):2375-89. doi: 10.1016/j.ejca.2014.06.007.

Huober J, Cole BF, Rabaglio M, Giobbie-Hurder A, Wu J, Ejlertsen B, Bonnefoi H, Forbes JF, Neven P, Láng I, Smith I, Wardley A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Gelber RD, Thürlimann B; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Symptoms of endocrine treatment and outcome in the BIG 1-98 study.

Breast Cancer Res Treat. 2014 Jan;143(1):159-69. doi: 10.1007/s10549-013-2792-7.

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.

Johnston SR, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, Im YH, Braybrooke JP, Brunt AM, Cheung KL, Jyothirmayi R, Robinson A, Wardley AM, Wheatley D, Howell A, Coombes G, Sergenson N, Sin HJ, Folkerd E, Dowsett M, Bliss JM; SoFEA investigators.

Lancet Oncol. 2013 Sep;14(10):989-98. doi: 10.1016/S1470-2045(13)70322-X.

Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.

Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pêgo A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, Melezínková H, Awada A.

J Clin Oncol. 2013 Jul 10;31(20):2586-92. doi: 10.1200/JCO.2012.46.2408.

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.

Rugo HS, Campone M, Amadori D, Aldrighetti D, Conte P, Wardley A, Villanueva C, Melisko M, McHenry MB, Liu D, Lee F, Pivot X.

Breast Cancer Res Treat. 2013 Jun;139(2):411-9. doi: 10.1007/s10549-013-2552-8.

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.


Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V.

J Clin Oncol. 2013 May 10;31(14):1719-25. doi: 10.1200/JCO.2012.44.7912.

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).

Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, Wardley A, Lichinitser M, Sanchez RI, Müller V, Dodwell D, Gelber RD, Piccart-Gebhart MJ, Cameron D.

Lancet Oncol. 2013 Mar;14(3):244-8. doi: 10.1016/S1470-2045(13)70017-2.

Emerging targeted combinations in the management of breast cancer.

Lee RJ, Armstrong AC, Wardley AM.

Breast Cancer (Dove Med Press). 2013 Aug 13;5:61-72. doi: 10.2147/BCTT.S26771.

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.

Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C; TRIO/BCIRG 001 investigators.

Lancet Oncol. 2013 Jan;14(1):72-80. doi: 10.1016/S1470-2045(12)70525-9.

Letrozole: advancing hormone therapy in breast cancer.

Lee RJ, Armstrong AC, Wardley AM.

Womens Health (Lond Engl). 2012 Nov;8(6):611-8. doi: 10.2217/whe.12.49.

Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.

Ferraldeschi R, Arnedos M, Hadfield KD, A'Hern R, Drury S, Wardley A, Howell A, Evans DG, Roberts SA, Smith I, Newman WG, Dowsett M.

Breast Cancer Res Treat. 2012 Jun;133(3):1191-8. doi: 10.1007/s10549-012-2010-z.

Our research focus in advanced breast cancer has been on introducing new treatments. Our clinical research trials take place in the at the Christie/NIHR clinical research facility, which is one of the largest Early Phase Trials Unit in the world. We have close links with the Clinical and Experimental Pharmacology Group at the Cancer Research UK Manchester Institute where investigations into the drug’s effect on the body (its pharmacodynamics) and the body’s effect on the drug (its pharmacokinetics) take place. We also have close research collaborations with the Wolfson Molecular Imaging Centre. Our group has been involved in early development of novel agents working with biotechnology companies, and driving evaluation of promising molecules from MCRC laboratory programmes, such as molecules that inhibit breast cancer stem cell self-renewal. We undertake first in combination trials of drugs relevant to breast cancer treatment and have close collaboration with Manchester Centre for Genomic Medicine. Finally, but not least, we are interested in translating clinical research into clinical practice and real world data.

Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes J, Thurlimann B, Paridaens R, Monnier A, Lang I, Wardley A, Nogaret JM, Gelber R, Castiglione-Gertsch M, Price K, Coates A, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A. (2007) Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol. May;18(5):859-67. Epub 2007 Feb 14

Smith I, Procter M, Gelber, RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ, and for the HERA study team (2007). 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. The Lancet 369; 9555: 29-36

Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret J-M, Pienkowski T, Wardley A, Jakobsen, EH, Price KN, Goldhirsch A. (2007). Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98. J Clin Oncol. 2007 Feb 10;25(5):486-92. Epub 2007 Jan 2.

Malinovsky K, Johnston S, Barrett-Lee P, Howell A, Verrill M, O’Reilly S,
Houston S, Wardley A, Grieve R, Leonard R. (2006). TEXAS (Taxotere(R) EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC. Cancer Chemother Pharmacol. 2006 Sep 29; [Epub ahead of print]

Wardley-A, (2006), Capecitabine: expanding options for the treatment of patients with early or locally advanced breast cancer. Oncologist. 2006;11 Suppl 1:20-6.

Board RE, Dean EJ, Mitchell C, Wardley-AM (2006) Second-line treatment of postmenopausal women with advanced breast carcinoma. Expert Rev Anticancer Ther. Apr;6(4):613-24.

Wardley-AM (2006), Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17. Clin Breast Cancer. Feb;6 Suppl 2:S45-50.

Dodwell D, Wardley A, Johnston S (2006). Postmenopausal advanced breast cancer: Options for therapy after tamoxifen and aromatase inhibitors. Breast. 2006 Feb 24; [Epub ahead of print]

Wardley-AM, Howell A (2006). Does HER2 overexpression affect response to endocrine therapy in advanced cancer? Nat Clin Pract Oncol. 2006 Feb;3(2):78-79.

Steger G., Gips M., Simon S., Lluch A., Vinholes J., Kaufman B., Wardley A., Mauriac L. (2005). Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme. Cancer Treat Rev. 2005;31 Suppl 2:S10-6. Epub 2005 Sep 28.

Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A; Breast International Group (BIG) 1-98 Collaborative Group (2005). A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005 Dec 29;353(26):2747-57. Erratum in: N Engl J Med. 2006 May 18;354(20):2200. Wardly, Andrew [corrected to Wardley, Andrew ].

Howell A, Wardley AM (2005). Overview of the impact of conventional systemic therapies on breast cancer. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S9-S16.

Chua S, Smith I.E., A’Hern RP, Coombes GA, Hickish TF, Robinson AC, Laing RW, O’Brien MER, Ebbs SR, Hong A, Wardley A, Mughal T, Verrill M, Dubois D, Bliss JM, (2005). Neoadjuvant Vinorelbine/Epirubicin (VE) versus Standard Adriamycin/Cyclophosphamide (AC) in Operable Breast Cancer: Analysis of Response and Tolerability in a Randomised Phase III Trial (TOPIC2). Ann Oncol. Sep;16(9):1435-41. Epub 2005 Jun 9.

Wardley AM, Davidson N, Barrett-Lee, Hong A, Mansi J, Dodwell D, Murphy R, Mason T and Cameron D. (2005). Zoledronic acid significantly improves pain scores and quality of life in patients with bone metastases: a randomised crossover study of community versus hospital bisphosphonate administration. Br J Cancer. May 23;92(10):1869-76.

Clayton A, Danson S, Jolly S, Ryder D, Burt P, Stewart A, Wilkinson P, Welch R, Magee B, Wilson G, Howell A, Wardley AM. (2004). Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. B J Cancer 91:639-643.

Wardley AM. Fulvestrant: a review of its development, pre-clinical and clinical data.
Int J Clin Pract. 2002 May;56(4):305-9. Review.